AstraZeneca Targets Global Obesity Market With Low-Cost Weight-Loss Drugs

AstraZeneca Plc’s playbook to break into the red-hot obesity market rests on improving upon existing medicines, offering competitive prices and leaning on its experience selling products in emerging markets.

The British drugmaker’s plan to develop easier-to-use drugs and target large volumes globally mirrors, at least in part, a template used for its blockbuster diabetes medicine Farxiga, Chief Executive Officer Pascal Soriot said Tuesday.